The Boston biotech Karuna Therapeutics, which is seeking approval of a novel drug for schizophrenia, is already talking about more than doubling its workforce next year if the Food and Drug ...

Karuna Therapeutics KRTX announced the submission of a new drug application (“NDA”) with the FDA seeking approval for its lead candidate KarXT, as a potential treatment of schizophrenia. If approved, ...

Karuna Therapeutics, Inc. KRTX announced a definitive agreement with Goldfinch Bio assignment estate to acquire global development, manufacturing and commercialization rights to the latter's transient ...

Karuna's stock closed up more than 47% on the news Friday, hitting $317.85 a share. Bristol Myers Squibb shares closed up 2%. The deal will help expand Bristol Myers' drug pipeline after competition ...

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (“Karuna,” formerly Karuna Pharmaceuticals), focused on targeting muscarinic cholinergic receptors for the treatment of neuropsychiatric disorders ...

NEW YORK (AP) — Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a biopharmaceutical company that has developed a new antipsychotic, in a $14 billion deal. Bristol Myers Squibb and ...

Karuna Therapeutics CEO Dr. Steve Paul says the biotech firm is hopeful its new therapy for schizophrenia will prove effective for patients in further clinical trials. "We're cautiously optimistic ...

Karuna Therapeutics focuses on therapies to treat neurological conditions. The stock is up more than 52% over the past year. The company has, as of the fourth quarter, $1.1 billion in cash, it said.